Ask the Expert: Targeted Therapies for Gliomas

What is targeted therapy for gliomas in children and adults?

Gliomas can be either low grade (LGG) or high grade (HGG) including anaplastic oligodendroglioma, anaplastic astrocytoma and glioblastoma multiforme.

Significant improvements have been made for initial therapy of HGG, especially in adults with combined chemoradiation using low dose temozolomide followed by temozolomide chemotherapy. However, HGG usually recur or progress after this combined treatment approach. There are many explanations for this, including cancer cell resistance to chemotherapy and abnormal cancer cell signalling, often due to gene mutations of components in these pathways.

Therapies that target specific proteins are known as targeted therapies. Recent studies of HGG have identified key growth factors and their receptors, including the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Targeted therapies use antibodies or small molecule inhibitors to block growth factors or their receptors, blocking glioma cell communication, growth and division.

Some targeted therapies have shown promise in patients with recurrent disease and are being studied in newly diagnosed HGG patients by adding them to standard treatment. However, the effectiveness of targeted therapies usually decreases over time since HGG are able to find ways to grow and invade normal brain despite specific treatment.

There is no established use for targeted therapies in LGG in children or adults outside of a clinical trial. However, there are special indications in LGG patients with inherited disorders such as Neurofibromatosis Type I (NFI) or Tuberous Sclerosis with subependymal giant cell astrocytoma (SEGA).

Patients with HGG are being entered on clinical trials to determine the best way to use these new drugs, including how to combine them with chemotherapy and identify which individual patients can benefit from their use. To date, most of these targeted therapies have shown less promise in children when compared to adults, suggesting that most pediatric HGG have a different biology than adult HGG.
 

You can download this information as a Brain Tumour Foundation of Canada Information Sheet (pdf).
Thank you to Dr David Eisenstat, MD, MA, FRCPC Director of Neuro-Oncology: Adult and Pediatric; CancerCare Manitoba,; Winnipeg, MB. Dr. Eisenstat is a member of the Profressional Advisory Group for Brain Tumour Foundation of Canada.

Return to Information Sheets here.

Share This

Featured Story

Courtney’s Story of Stability

Stability. It’s a strange concept when you have what it known to be a progressive, life long illness. You hear the words, “Your tumour growth is stable” and for a moment you think someone is playing the world’s worst prank on you.

Learn more

Spotlight

Stephen's Story: "I have faith that we will meet again"

Stephen and I chatted on what should have been his 32nd Wedding Anniversary. Stephen and Susan were married for 30 years and were best...

Learn more

Tommy's Story: Fellowship recipient

Dr. Tommy Alain, the very first research Fellow funded by Brain Tumour Foundation of Canada through the William Donald Nash Brain...

Learn more

Upcoming Events

  • 23/Jan/2018: Groupe de soutien virtuel: Un groupe de soutien virtuel pour personnes touchées par une tumeur... Learn more >
  • 25/Jan/2018: Virtual Support Group East: Virtual Support Group for Eastern Canada... Learn more >
  • 25/Jan/2018: Sarnia Support Group: Meets at St. Giles Presbyterian Church,770 Lakeshore Road Sarnia, ON... Learn more >
  • 29/Jan/2018: Greater Sudbury Support Group: Meets at The Parkside Centre, 140 Durham Street, Sudbury, Ontario... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2018 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
35 Years